Osage University Partners is among the series B investors backing Virginia Tech-linked IBD therapy disease developer Landos Biopharma, which is preparing phase 2 trials.
The spinout has revealed it added approximately $6m to a series A round backed by University of Pennsylvania and IP Group last year, bringing its total size to about $59m.
Allied Minds has returned again for a series B round that took the firm's geospatial data analytics technology subsidiary's total funding to about $96m.
Novo, Partners Healthcare and Sham all contributed to a $74.6m round for Alizé Pharma 3, which is exploiting research from three US institutions.
UTokyo IPC, Keio Innovation Initiative and Innovations and Future Creation have contributed to a $79.7m series A that increased the Tokyo spinout's total funding to about $100m.
Harvard Medical School spinout TScan has come out of stealth with $48m in funding provided by investors including GV and two Novartis units.
Johnson & Johnson, Alexandria Venture Investments and Serum Institute of India contributed to a series A for Albert Einstein College of Medicine spinout X-Vax.
A host of individuals connected with the e-commerce industry have supplied capital, enabling Stanford-linked company Bolt to target its next phase of expansion.